Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s
Executive Summary
One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.
You may also be interested in...
Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal
Alzheimer’s community stakeholders are planning a unified response to a CMS Medicare coverage proposal that would, in their view, disastrously constrain use of PET imaging, and imaging agents like Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.
Lilly Submits New Amyvid Data For Medicare National Coverage Analysis
Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.
Medicare Coverage Decision For Amyvid Due July 2013
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.